Please ensure Javascript is enabled for purposes of website accessibility

Walgreen's Wonderful Comps

By Steven Mallas – Updated Nov 16, 2016 at 2:36PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This drugstore chain doesn't need any medical attention. January comps prove it.

Walgreen (NYSE:WAG) reported its January same-store sales figures a couple days ago, and, although I am no clairvoyant, I am going to go out on a limb and predict that Fools who own shares in this company are sporting a grin of satisfaction at the numbers and the prognosis they imply.

To begin with, sales in total for the first month of 2005 came in at $3.466 billion compared with $3.031 billion in January 2004, representing growth of 14%. Here's the crux, though: Same-store results showed an even 10% increase. Something certainly was going on at Walgreen last month (as opposed to nothing) -- and that something was a lot of green being collected at the points of sale.

Good news from this retail pharmacy is becoming a bit of a bore by now (oh, I can hear the collective angry musings out there, in hissing tones, screaming this warning on some telekinetic wavelength: Don't jinx it, you idiot!). In fact, I wrote about comps figures for Walgreen's September 2004 frame and found them to be close to 10% then (the actual number was 9.3%). I also wrote about the June sales results last summer: Once again, the company scored.

Walgreen obviously is in the midst of a solid trend of sales growth. The stock also has been growing the past 52 weeks, as its chart shows. Long-term investors who want to be in this space have two biggies to choose from: the subject of this piece (naturally), as well as CVS (NYSE:CVS). Rite Aid (NYSE:RAD) has been having a difficult time getting its business back on track, and its stock reflects the negative outlook. For an example of some of the challenges Rite Aid has faced, check out a recent Take written by Nathan Slaughter.

So, the moral of the story -- at this time, at least -- is to stay away from the more speculative Rite Aid and take a look at either CVS or Walgreen. Let me say this, however: Trends are indeed made to be broken. Remember that fundamentally sound companies do nevertheless stumble and cycle as the years go by. I showed you a one-year chart of Walgreen earlier -- how about a three-year chart? A little more volatile, eh? That's OK, though -- volatility is the companion of the long-term-investing sojourner. Just make sure you bring along one other companion on the journey -- Mr. Dollar Cost Average. He'll always be at your service.

For more information on the drugstore industry, see:

Fool contributor Steven Mallas owns none of the companies mentioned. To get involved with the Foolish conversation on Walgreen and its competitors, head on over to the company's discussion board.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

CVS Health Corporation Stock Quote
CVS Health Corporation
CVS
$98.35 (-1.48%) $-1.48
Walgreens Boots Alliance, Inc. Stock Quote
Walgreens Boots Alliance, Inc.
WBA
$32.83 (-1.47%) $0.49
Rite Aid Corporation Stock Quote
Rite Aid Corporation
RAD
$7.01 (-0.99%) $0.07

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
109%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.